Drug Discovery용 인공지능(AI) 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Artificial Intelligence (AI) in Drug Discovery Market size is expected to reach USD 35.68 Billion in 2034 from USD 3.36 Billion (2025) growing at a CAGR of 30.04% during 2026-2034.

The AI in drug discovery market has witnessed significant growth as pharmaceutical companies seek to reduce R&D timelines and costs. AI technologies-such as machine learning, deep learning, and natural language processing-are used to identify drug targets, predict molecular behavior, and optimize clinical candidate selection. Growing collaboration between biotech startups and large pharmaceutical firms has accelerated AI adoption in early-stage research.

Primary drivers include rising drug development costs, the need for higher success rates, and access to vast biomedical datasets. AI platforms enhance target validation, compound screening, and toxicity prediction, shortening discovery cycles. Advances in computational power and cloud-based analytics further support scalability. Venture capital investment in AI-driven biotech firms has fueled innovation and expanded the competitive landscape.

Looking ahead, AI is expected to become integral across the drug development continuum, including clinical trial design and real-world evidence analysis. Integration with genomics, proteomics, and patient data will enable more precise therapies. Regulatory acceptance of AI-generated insights and data transparency will influence long-term growth. As algorithms mature and validation improves, AI-driven pipelines may significantly reshape pharmaceutical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Drug Optimization and Repurposing
• Preclinical Testing
• Others

By Therapeutic Area

• Oncology
• Neurodegenerative Diseases
• Cardiovascular Disease
• Metabolic Diseases
• Infectious Disease
• Others

COMPANIES PROFILED

• IBM Corporation, Exscientia plc, Insilico Medicine Inc, Aitia formerly GNS Healthcare, Google DeepMind, BenevolentAI, BioSymetrics Inc, Berg Health acquired by BPGbio, Atomwise Inc, insitro, Cyclica now part of Recursion Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Drug Optimization and Repurposing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By Therapeutic Area
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By Therapeutic Area
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By Therapeutic Area
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By Therapeutic Area
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By Therapeutic Area
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 IBM Corporation
  • 8.2.2 Exscientia Plc
  • 8.2.3 Insilico Medicine Inc
  • 8.2.4 Aitia (Formerly GNS Healthcare)
  • 8.2.5 Google DeepMind
  • 8.2.6 BenevolentAI
  • 8.2.7 BioSymetrics Inc
  • 8.2.8 Berg Health (Acquired By BPGbio)
  • 8.2.9 Atomwise Inc
  • 8.2.10 Insitro
  • 8.2.11 Cyclica (Now Part Of Recursion Pharmaceuticals)